ClinicalTrials.gg

Program

TR115

A development code.

Its studies are mostly in Endometrial Neoplasms · Lymphoma, Extranodal NK-T-Cell · Lymphoma, Non-Hodgkin, led by Tarapeutics Science.

Furthest: phase 3, since May 26, 20263 company-led studies, 3 open or runningNext primary completion: May 1, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tarapeutics Science33 open or runningphase 3since May 26, 2026Dec 6, 2022May 1, 2028phase 2 · NCT07793318

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 6, 2022First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT05650580 · 26 planned · China
  2. May 26, 2026Phase 3 study in Lymphoma, Extranodal NK-T-CellPhase 3 reachedNCT07639879 · 180 planned · China
  3. Aug 25, 2026Phase 2 study in Endometrial NeoplasmsNCT07793318 · 50 planned · China

Ahead

  1. May 1, 2028Primary completion: phase 2 study in Endometrial NeoplasmsNCT07793318
  2. Jul 30, 2029Primary completion: phase 3 study in Lymphoma, Extranodal NK-T-CellNCT07639879

TargetBeta

EZH2 →read by rule
“This is an open-label, multicenter, exploratory Phase II study to evaluate the efficacy and safety of TR115, an EZH2 inhibitor, in patients with advanced solid tumors carrying ARID1A gene mutations.”study text, by rule · the study

Other programs on EZH2

ProgramCompanyFurthest phaseStudies
zeprumetostatruleJiangsu HengRui Medicinephase 317
mevrometostatPfizerphase 37
tulmimetostatNovartisphase 23
EZH1/2 Inhibitor HH2853ruleHaihe Biopharmaphase 22
valemetostatruleDaiichi Sankyophase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07793318Endometrial Neoplasms · China2Not yet recruitingMay 1, 202850
NCT07639879Lymphoma, Extranodal NK-T-Cell · China3Not yet recruitingJul 30, 2029180
NCT05650580Lymphoma, Non-Hodgkin · China1RecruitingJul 30, 202526

How it is read

Names in the registry

  • “TR115”, 3 entries

Codes read as this program: TR115.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.